Nanoscope Therapeutics Awarded ‘Best of Show’ for Retina at Eyecelerator@AAO 2023
DALLAS, TX (November 3, 2020) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), has been awarded “Best of Show for Retina” at Eyecelerator@AAO2023. The award was presented to Nanoscope’s Chief Medical Officer, Samuel Barone, MD, for his presentation during the event’s Retina Showcase. In his presentation Dr. Barone showcased the company’s Multi-Characteristic Opsin platform and its potential to restore vision based on recent clinical data in patients with advanced retinal degenerative diseases.
Recipient of the Best of Show Award is chosen by a vote of conference attendees. “We are thrilled and honored for this recognition,” said Sulagna Bhattacharya, CEO, “It is very special because it comes from our own retina community. We thank you all for the encouragement. It means a great deal to our entire team.”
“The patient experience was front and center in my presentation, and I appreciate the acknowledgment of our work to make a difference in their lives,” said Samuel Barone, CMO.
Eyecelerator@AAO2023 took place on November 2, 2023 in advance of the American Academy of Ophthalmology Annual Meeting in San Francisco. Eyecelerator focuses on emerging trends, advancements and innovations in eyecare.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.
SOURCE Nanoscope Therapeutics